Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer

Date

21 Oct 2023

Session

Poster session 14

Topics

Laboratory Diagnostics;  Genetic and Genomic Testing

Tumour Site

Prostate Cancer

Presenters

Xin Ye

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

X. Ye1, U. Singh2, P. Cheng3, Y. Guo4, J. Wang4, K. Bell5, K. Urtishak6, L. Luo1, X. Lyu1, W. Xu4, Z. Huang3, X. Chen4, S. Liu7, S. Yang4, W. Shi4, M. Gormley6, D.A. Smirnov6, L. Zhou1, C. Zhu3

Author affiliations

  • 1 Oncology Translational Research Asia, Janssen Research & Development, 201210 - Shanghai/CN
  • 2 Precision Medicine And Diagnostics, Janssen Research & Development, 08869 - Raritan/US
  • 3 Translational Medicine, Amoy Diagnostics Co., Ltd., 361027 - Xiamen/CN
  • 4 R&d, Amoy Diagnostics Co., Ltd., 361027 - Xiamen/CN
  • 5 Biomarker And Diagnostic Operation, Janssen Research & Development, 19477 - Spring House/US
  • 6 Oncology Translational Research, Janssen Research & Development, 19477 - Spring House/US
  • 7 Companion Diagnosis, Amoy Diagnostics Co., Ltd., 361027 - Xiamen/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1213P

Background

HRR gene alterations, which are enriched in prostate cancer (PC), are associated with sensitivity to PARP inhibitors. However, the tests available to detect HRR gene alterations are limited and usually large NGS panels with high cost and long turnaround time (TAT). A novel HANDLE (Halo-shape ANnealing and Defer-Ligation Enrichment) based NGS assay, AmoyDx HRD Complete was established to evaluate single nucleotide variant (SNV), short insertion and deletion (InDel) and homozygous deletion (HD) of 17 HRR genes in PC tissues, with 4 days TAT.

Methods

Sensitivity was validated in serially diluted cell lines with varying DNA input: with gradient mutation allele frequency (MAF) (7%, 5%, 3%) for SNV/InDel; with different tumor content (50%, 40%, 30%, 20%) for HD. Specificity was validated in wild type cell lines. Testing success rate was evaluated using 100 formalin-fixed paraffin-embedded (FFPE) PC tissues (up to 10 years old). A “three-tube” library process was developed for samples which failed DNA, library, or sequencing QC with standard process. Accuracy was assessed in >200 FFPE PC tissues, using commercially available AmoyDx HRD54 NGS kit (hybridization capture based) and AmoyDx BRCA1/2 NGS kit (CE-IVD) as reference tests.

Results

Sensitivity of HRR SNV/InDel was 99.4% (179/180, MAF 5%) with 30ng DNA. Sensitivity of HRR HD was 100% at gene level with 30% tumor content and at exon level with 40% tumor content with 100ng DNA. Specificity was 100%. 54/100 (54%) PC tissues had valid sequencing results using standard process, whereas the “three-tube” library improved the success rate to 84%. For HRR SNV/InDel accuracy, 98/100 PC tissues showed concordant results with HRD54 kit (PPA 96.8%, NPA 98.6%, OPA 98.0%). For HRR HD accuracy, 130/132 PC tissues showed concordant results with HRD54 kit (PPA 100%, NPA 98.4%, OPA 98.5%). Accuracy of BRCA1/2 SNV/InDel was further verified with 100% concordance with BRCA1/2 kit.

Conclusions

With high sensitivity and specificity, short TAT and high success rate, the CE marked (CE-IVD) HRD Complete assay provides a robust and reliable test approach to PC patients that may guide them for a better treatment option.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Janssen.

Disclosure

X. Ye, U. Singh, K. Bell, K. Urtishak, L. Luo, X. Lyu, M. Gormley, D.A. Smirnov, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Johnson and Johnson. P. Cheng, Y. Guo, J. Wang, W. Xu, Z. Huang, X. Chen, S. Liu, S. Yang, W. Shi, C. Zhu: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.